Personalis Gains Medicare Coverage for NeXT Personal in Lung Cancer Surveillance
Personalis has secured Medicare reimbursement for its NeXT Personal liquid biopsy in lung cancer surveillance, covering post‐treatment patient monitoring nationwide. This decision enables billing under Medicare’s Clinical Laboratory Fee Schedule and opens potential revenue from millions of beneficiaries.
1. Medicare Coverage Approval
Personalis has obtained national Medicare reimbursement for its NeXT Personal liquid biopsy in lung cancer surveillance, enabling billing under the Clinical Laboratory Fee Schedule. The approval covers surveillance testing for Medicare beneficiaries diagnosed with lung cancer post‐treatment.
2. Market Potential
The coverage decision opens access to millions of patients, potentially driving significant revenue growth as oncology centers integrate the test into routine monitoring. Personalis expects accelerated adoption and higher lab volume as clinicians leverage the assay for early recurrence detection.
3. Test Description
NeXT Personal employs targeted sequencing and proprietary analytics to detect minimal residual disease via circulating tumor DNA, offering high sensitivity for early recurrence alerts. The test complements imaging protocols and supports personalized treatment decisions to improve patient outcomes.